Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.52 |
| ▸ | RELA | Q04206 | 1/20 | 0.52 |
| ▸ | BACE1 | P56817 | 16/20 | 0.45 |
| ▸ | BACE2 | Q9Y5Z0 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | APP | P05067 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14059199 | 0.89 | SMN1; SMN2 (0.54) | SMN1; SMN2RAB9ANPC1TP53MAPT | |
| SCHEMBL14957803 | 0.89 | NPC1 (0.51) | SMN1; SMN2RAB9ANPC1TP53MAPT | |
| SCHEMBL14059153 | 0.83 | SMN1; SMN2 (0.52) | SMN1; SMN2RAB9ANPC1TP53MAPT | |
| SCHEMBL14059097 | 0.83 | SMN1; SMN2 (0.52) | SMN1; SMN2RAB9ANPC1TP53MAPT | |
| SCHEMBL14060001 | 0.78 | NPC1 (0.53) | SMN1; SMN2RAB9ANPC1TP53MAPT | |
| Hydrochloric Acid SCHEMBL14059177 | 0.77 | SMN1; SMN2 (0.45) | SMN1; SMN2RAB9ANPC1TP53MAPT | |
| SCHEMBL14059228 | 0.72 | SLC6A3 (0.40) | RAB9ANPC1 | |
| SCHEMBL14059627 | 0.72 | GAA (0.41) | RAB9ANPC1 | |
| SCHEMBL14957999 | 0.71 | BACE1 (0.45) | SMN1; SMN2RAB9ANPC1TP53MAPT | |
| SCHEMBL14958228 | 0.71 | BACE1 (0.45) | SMN1; SMN2RAB9ANPC1TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8604024-B2 | Compounds for the reduction of beta-amyloid production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-12-10 | — | — | US | disclosed |
| US-20130131051-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2013-05-23 | — | — | US | disclosed |
| WO-2012162330-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS FOR THE PRODUCTION OF BETA-AMYLOID | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131051-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | APP, BACE1, SCN2B | SMN1; SMN2 796/4885RAB9A 4510/4885NPC1 413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.